The decrease in the expression levels of survivin, MMP-9, Bcl-2/xl, VEGF, and COX-2 suggests that the NF-κB targeting drugs could modulate the survival and growth of CML cells by promoting apoptosis. Here, BIRC5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.